Top Markets
#1 Black Phoenix Black Phoenix +166.18%
#2 Islamic Coin Islamic Coin +158.21%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +20.80%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.53%
#6 MarsCoin MarsCoin +13.34%
#7 Test Test +12.58%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +11.52%
#9 Palladium Network Palladium Network +9.76%
#10 Useless Coin Useless Coin +9.21%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Classifica tra le azioni #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Prezzo delle azioni
$0.0005
Ultima sincronizzazione: 2026-08-11
Capitalizzazione di mercato
$10.28K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia VIA Pharmaceuticals, Inc. (VIAP)

Categoria

Healthcare
EPS per VIA Pharmaceuticals, Inc. (VIAP)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di VIA Pharmaceuticals, Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per VIA Pharmaceuticals, Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.41 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $0.52 -
US